2015
DOI: 10.1016/j.schres.2015.05.017
|View full text |Cite
|
Sign up to set email alerts
|

Dysfunctional glycosynapses in schizophrenia: Disease and regional specificity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
11
0
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 25 publications
(14 citation statements)
references
References 19 publications
0
11
0
3
Order By: Relevance
“…[112, [198][199][200] Increased PlsEtn levels in postmortem brain tissue of AD patients [205] Decreased PlsCho levels in prefrontal cortex autopsy tissue of patients [201] Decreased PlsEtn levels in plasma of AD patients and in serum of patients with cognitive impairment [207,208,210] Decreased PlsEtn levels in brain tissue derived from mouse models of the disease (APPswe/PS1-dE9 transgenic; APPswe/tauP301L transgenic) [203,204] Reduced ADHAPS protein levels (but increased AGPS mRNA levels) in brain tissue of patients; dysregulation of expression of ether lipid biosynthetic enzymes in brain and cultured cells of mouse models deprived of Ab peptides (PS 1/2 KO, APP KO, APP/APLP 2 KO) [215] Increased activity of plasmalogen-selective phospholipase A2 in several brain regions of AD patients [214] Reduced activity of c-secretase upon treatment with different PlsEtn or PlsCho species in vitro [218] Accumulation of C16:0-PAF and C16:0-lyso-PAF in posterior/entorhinal cortex of AD patients and of an AD mouse model (TgCRND8; transgenic APPswe/ind double mutation) [223] Impaired binding of PAF to platelets of patients with AD or multiinfarct dementia [238] Parkinson's disease Reduced levels of plasmalogens with C16:0 at sn-1 in plasma of PD patients [239] Reduced levels of plasmalogens in lipid rafts isolated from cortical gray matter of PD patients [240] Reduced PlsEtn levels in serum of MPTP-treated mice (a model of PD) [241] Relief of dyskinetic side effects of levodopa in Parkinsonian monkeys by treatment with a plasmalogen precursor [242] Down syndrome Reduced PlsEtn levels in frontal cortex and cerebellum of patients (but associated with a general decrease in ethanolamine phospholipids) [243] Reduced plasmalogen levels in erythrocytes of patients [244] Schizophrenia Elevated levels of some PlsCho and PlsEtn species in frontal cortex of patients and of a mouse model of the disease (G72/G30 transgenic) [245,246] Reduced plasmalogen levels in plasma of first episode and recurrent patients [247] Reduced PlsEtn levels in plasma and platelets of patients; decreased PlsCho levels in plasma, but increased levels in platelets of patients [248] Reduced levels of several plasmalogen species in fibroblasts f...…”
Section: Disease Reported Involvement Of Ether Lipidsmentioning
confidence: 99%
“…[112, [198][199][200] Increased PlsEtn levels in postmortem brain tissue of AD patients [205] Decreased PlsCho levels in prefrontal cortex autopsy tissue of patients [201] Decreased PlsEtn levels in plasma of AD patients and in serum of patients with cognitive impairment [207,208,210] Decreased PlsEtn levels in brain tissue derived from mouse models of the disease (APPswe/PS1-dE9 transgenic; APPswe/tauP301L transgenic) [203,204] Reduced ADHAPS protein levels (but increased AGPS mRNA levels) in brain tissue of patients; dysregulation of expression of ether lipid biosynthetic enzymes in brain and cultured cells of mouse models deprived of Ab peptides (PS 1/2 KO, APP KO, APP/APLP 2 KO) [215] Increased activity of plasmalogen-selective phospholipase A2 in several brain regions of AD patients [214] Reduced activity of c-secretase upon treatment with different PlsEtn or PlsCho species in vitro [218] Accumulation of C16:0-PAF and C16:0-lyso-PAF in posterior/entorhinal cortex of AD patients and of an AD mouse model (TgCRND8; transgenic APPswe/ind double mutation) [223] Impaired binding of PAF to platelets of patients with AD or multiinfarct dementia [238] Parkinson's disease Reduced levels of plasmalogens with C16:0 at sn-1 in plasma of PD patients [239] Reduced levels of plasmalogens in lipid rafts isolated from cortical gray matter of PD patients [240] Reduced PlsEtn levels in serum of MPTP-treated mice (a model of PD) [241] Relief of dyskinetic side effects of levodopa in Parkinsonian monkeys by treatment with a plasmalogen precursor [242] Down syndrome Reduced PlsEtn levels in frontal cortex and cerebellum of patients (but associated with a general decrease in ethanolamine phospholipids) [243] Reduced plasmalogen levels in erythrocytes of patients [244] Schizophrenia Elevated levels of some PlsCho and PlsEtn species in frontal cortex of patients and of a mouse model of the disease (G72/G30 transgenic) [245,246] Reduced plasmalogen levels in plasma of first episode and recurrent patients [247] Reduced PlsEtn levels in plasma and platelets of patients; decreased PlsCho levels in plasma, but increased levels in platelets of patients [248] Reduced levels of several plasmalogen species in fibroblasts f...…”
Section: Disease Reported Involvement Of Ether Lipidsmentioning
confidence: 99%
“…Recently, some postmortem brain studies have reported alterations in the levels of several plasmalogen species in patients with schizophrenia and BP; however, contradictive negative results have also been reported . One study examined plasmalogen levels in red cell membrane among patients with BP I and healthy controls; however, there were no significant differences between the two groups .…”
mentioning
confidence: 99%
“…14 Long-term treatment with lithium or valproate enhances mitochondrial function in vitro and protects methamphetamine-induced neurotoxicity at the mitochondrial level in vivo. 15 Recently, some postmortem brain studies have reported alterations in the levels of several plasmalogen species in patients with schizophrenia 16,17 and BP 17 ; however, contradictive negative results have also been reported. [18][19][20] One study examined plasmalogen levels in red cell membrane among patients with BP I and healthy controls; however, there were no significant differences between the two groups.…”
mentioning
confidence: 99%
“…2 приведен пример окрашивания при ECL-иммуноблоттинге иммунореактивной КФК В во фрак-ции водорастворимых белков мозжечка. Видно, что ин-тенсивность окрашивания полосы, соответствующей КФК В, в контроле значительно выше (дорожки 1-9), чем у больных ШЗ (10)(11)(12)(13)(14)(15)(16)(17). Как и активность КФК, ко-личество иммунореактивной КФК В во всех анализиро-ванных областях мозга было значительно снижено у больных ШЗ по сравнению с контролем (во всех случаях р<0,01) (рис.…”
Section: количество иммунореактивной кфк в во фракции водорастворимыхunclassified
“…По данным литературы [7,10], при ШЗ в этих структурах мозга, особенно в ПФК и лимби-ческой коре, происходят значительные метаболические нарушения.…”
unclassified